Publisher
Springer Science and Business Media LLC
Reference93 articles.
1. Griffiths, G., Hall, R., Sylvester, R., Raghavan, D. & Parmar, M. K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171–2177 (2011).
2. Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder. Cancer 349, 859–866 (2003). This was the first randomized trial in MIBC that included pCR as a key end point, reported pCR results in neoadjuvant chemotherapy and control arms, and also survival results according to pCR status.
3. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202–205; discussion 205–206 (2005).
4. Thompson, R. H. et al. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 113, E17–E21 (2014).
5. Jiang, D. M. et al. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat. Rev. Urol. 18, 104–114 (2021).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献